Gilead Sciences' Hepcludex Approved by FDA for Chronic HDV Infection
The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences' Hepcludex (bulevirtide), marking the first-ever therapy for chronic hepatitis delta virus (HDV) infection. The approval was based on phase 3 trial results showing a significantly better combined response in patients receiving Hepcludex.
Tickers: $GILD
Topics: drug approval hepatitis delta virus (HDV) pharmaceuticals